accountresults from the CATT trial provide evidence that Avastin's cost savings outweigh its potential risks in Wet AMD. Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to AlphaDetail AlphaPulse���: Anticipated Impact Of CATT Trial In Wet AMD Treatment
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account